Chronic lymphocytic leukemia (CLL) remains an incurable disease. Rituximab and fludarabine are two of the most effective agents in CLL update. Despite the widespread use of highly effective chemoimmunotherapy, fludarabine-refractory CLL remains a challenging problem associated with poor overall survival. Approved therapeutic options for these patients remain limited. Fortunately, allogenetic stem cell transplantation (allo-SCT) and several novel targeted therapeutics in clinical trails hold promise of significant benefit for these patients' population. This review discusses the activity of available and novel targeted therapeutics besides allo-SCT in fludarabine-refractory or fludarabine-resistant CLL.
|Original language||English (US)|
|Number of pages||4|
|Journal||Journal of Leukemia and Lymphoma|
|State||Published - Sep 1 2013|
ASJC Scopus subject areas
- Cancer Research